Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castrate-sensitive progressive disease. Community urologists often treat PC patients many years before the development of progressive disease, and a growing number of urologists have successfully implemented advanced prostate cancer clinics (APCCs) within their practice setting in order to do so. This interactive activity will discuss the benefits of creating an APCC as well as all of the infrastructure requirements and practical considerations for administering chemotherapy in an office setting, as well as the financial ramifications of this investment in time and resources.
From breast cancer to myeloma and gastric cancer, Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of oncology subject matters.
This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.
Welcome to Progress in Pleural Mesothelioma, an Elsevier Learning Center. The aim of this learning center is to increase clinical knowledge by providing continuing medical education (CME) activities, research articles, and resources for health care professionals (HCPs) who treat patients with pleural mesothelioma.
Biosimilars, which have been available in Europe for more than 10 years, are increasingly gaining regulatory approval in the United States. These agents have the potential to contain rapidly increasing health care costs and simultaneously enable greater patient access. The cornerstone of broad acceptance of biosimilars is increased education of all involved parties regarding regulatory standards for biosimilar approval, preclinical and clinical data requirements, interchangeability, and extrapolation of indications.
ASCO & ESMO 2017 Highlights: Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment ParadigmsFormat: Webcast
The goal of this initiative is to help medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.
Join us to test and expand your knowledge on the increasingly important role of biomarkers in immuno-oncology. Three leading experts will challenge you with quiz questions that lay the basis for in-depth discussions supported by slide presentations. In this interactive learning experience we will examine the tumor microenvironment and address the evidence base and the future potential of current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. You will also learn about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for your daily clinical practice.
Community oncologists are challenged to stay up to date with updated clinical practice guidelines on the personalization of treatments for genitourinary (GU) cancers, including prostate, urothelial, and renal cancers, combination/sequential therapies, emerging safety and efficacy data from ongoing studies of novel regimens, and strategies to facilitate patient engagement in order to improve patient outcomes. Clinicians need tools and resources to help educate their patients and empower them to participate in their care and make educated treatment choices. Advanced-stage GU cancers consists of a spectrum of disease that requires an integrated multidisciplinary approach supported by a uro-oncologic team. Therefore, it is critical to educate these clinicians on their roles within the multidisciplinary cancer care team and on the importance of effective communication with other members of the team to maximize patient outcomes.
This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.
Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.
This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.
This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.
This webcast on gastric cancer (GC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of GC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, and the 2017 ASCO Annual Meeting, held in Chicago, USA. Advances in perioperative treatment strategies, targeted therapies such as HER2 inhibitors, and novel immunotherapies including agents targeting PD-1/PD-L1 will be examined. The experts will address the question of how novel treatment options, when approved, could be included in individualized treatment plans, to optimize treatment selection and outcomes for patients with GC.
ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular CarcinomaFormat: Medical Meeting Reporter
This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.
Metastatic melanoma has a high mortality rate and is refractory to traditional treatments, but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This webinar will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.
Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ASCO 2017 – Expert DiscussionFormat: Webcast
Immunotherapy is now an established treatment approach for patients with cancer across oncology. Immunotherapy agents are a newer type of anticancer drug, and the drugs in the largest class, checkpoint inhibitors, block the checkpoint pathways that cancer cells use to shut down the patient’s immune system. Checkpoint inhibitors are associated with more durable clinical responses compared to both small molecule targeted therapy and conventional chemotherapy (CT). Because checkpoint inhibitors have unique mechanisms of action, they also produce immune-related adverse events and response patterns that are markedly distinct from targeted agents or conventional CT. The 5 currently available immunotherapy agents have 18 indications across multiple cancer types. Checkpoint inhibitors demonstrate the potential to change current cancer treatment paradigms.
In this interactive CE activity, a leading medical oncologist discusses highlights of several key presentations from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on the use of checkpoint inhibitors in several cancer types. Topics include questions on appropriate clinical setting for immunotherapy (eg, refractory cancer), dose, combination therapy, treatment beyond progression, and side-effect profile for patients.